Differences in the frequencies of K-ras c12-13 genotypes by gender and pathologic phenotypes in colorectal tumors measured using the allele discrimination method

Environmental and Molecular Mutagenesis

Volumn 53, Issue 1, 2012, Pages 22-31

  Chow, Lihui ^a   Lin, Peng Chan ^b   Chang, Jeffrey S ^a   Chu, Pei Yi ^c   Lee, Pao Kung ^a   Chen, Shan Na ^a   Cheng, Ying Min ^a   Lee, Jenq Chang ^b   Chang, Jang Yang ^a   Liu, Tsang Wu ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c St Martin De Porres Hospital   (Taiwan)

Author keywords

Allele discrimination; CRC pathologic phenotypes; Dual color real time PCR; GAT prevalence; K ras codon 12 13 mutations

Indexed keywords

K RAS PROTEIN;

AGED; ARTICLE; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; TUMOR DIFFERENTIATION;

AGE FACTORS; AGED; ALLELES; CELL LINE, TUMOR; CODON; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; SEX FACTORS;

EID: 84855431206     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20673     Document Type: Article

References (37)

1. Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS. 2009. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 219: 435-445.
2. Akagi K, Uchibori R, Yamaguchi K, Kurosawa K, Tanaka Y, Kozu T. 2007. Characterization of a novel oncogenic K-ras mutation in colon cancer. Biochem Biophys Res Commun 352: 728-732.
3. Al-Mulla F, Going JJ, Sowden ET, Winter A, Pickford IR, Birnie GD. 1998. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol 185: 130-138.
4. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. 2008. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
5. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. 1998. Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study. J Natl Cancer Inst 90: 675-684.
6. Baisse B, Bouzourene H, Saraga EP, Bosman FT, Benhattar J. 2001. Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer 93: 346-352.
7. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G, Salerno S, Tomasino RM, Labianca R, Gebbia N, Russo A. 2002. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13: 1438-1446.
8. Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G. 1994. K-ras mutation in colorectal cancer: Relations to patient age, sex and tumour location. Br J Cancer 69: 367-371.
9. Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM, Smits KM, de Bruine AP, Goldbohm RA, van den Brandt PA. 2003. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24: 703-710.
10. Chang YS, Yeh KT, Chang TJ, Chai C, Lu HC, Hsu NC, Chang JG. 2009. Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer 9: 179.
11. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A. 2008. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 8: 142.
12. Edkins S, O'Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S, Hunter C, Smith R, Stephens P, Goldstraw P, Nicholson A, Chan TL, Velculescu VE, Yuen ST, Leung SY, Stratton MR, Futreal PA. 2006. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 5: 928-932.
13. Gallegos Ruiz MI, Floor K, Rijmen F, Grunberg K, Rodriguez JA, Giaccone G. 2007. EGFR and K-ras mutation analysis in non-small cell lung cancer: Comparison of paraffin embedded versus frozen specimens. Cell Oncol 29: 257-264.
14. Kobunai T, Watanabe T, Yamamoto Y, Eshima K. 2010. The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: A comparison between direct sequencing and real-time PCR. Biochem Biophys Res Commun 395: 158-162.
15. Lee JC, Wang ST, Lai MD, Lin YJ, Yang HB. 1996. K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res 16: 3839-3844.
16. Lefferts JA, Tsongalis GJ, Suriawinata AA, Funkhouser WK, Ladanyi M, Nowak JA, Pipas JM. 2010. KRAS mutation detection: A new look at an old gene. Clin Chem 56: 698-701.
17. Li CF, Huang WW, Wu JM, Yu SC, Hu TH, Uen YH, Tian YF, Lin CN, Lu D, Fang FM, Huang HY. 2008. Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors. Clin Cancer Res 14: 7822-7831.
18. Losi L, Baisse B, Bouzourene H, Benhattar J. 2005. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 26: 916-922.
19. Marchetti A, Gasparini G. 2009. K-ras mutations and cetuximab in colorectal cancer. N Engl J Med 360: 833-834. Author reply 835-836.
20. Miyakura Y, Sugano K, Fukayama N, Konishi F, Nagai H. 2002. Concurrent mutations of K-ras oncogene at codons 12 and 22 in colon cancer. Jpn J Clin Oncol 32: 219-221.
21. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. 2009. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205: 858-862.
22. Ohnishi T, Tomita N, Monden T, Ohue M, Yana I, Takami K, Yamamoto H, Yagyu T, Kikkawa N, Shimano T, Monden M. 1997. A detailed analysis of the role of K-ras gene mutation in the progression of colorectal adenoma. Br J Cancer 75: 341-347.
23. Pajkos G, Kiss I, Sandor J, Ember I, Kishazi P. 2000. The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res 20: 1695-1701.
24. Palmirotta RSA, Formica V, Ludovici G, Del Monte G, Roselli M, Guadagni F. 2009. A novel K-ras mutation in colorectal cancer. A case report and literature review. Anticancer Res 29: 3369-3374.
25. Poehlmann AKD, Meyer F, Lippert H, Roessner A, Schneider-Stock R. 2007. K-ras mutation detection in colorectal cancer using pyrosequencing technique. Pathol Res Pract 203: 489-497.
26. Rouleau E, Spyratos F, Dieumegard B, Guinebretiere JM, Lidereau R, Bieche I. 2008. KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: The need for a more precise definition. Br J Cancer 99: 2100.
27. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. 2000. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study. Cancer Epidemiol Biomarkers Prev 9: 1193-1197.
28. Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R, Nobili S, Mini E, Pazzagli M, Orlando C. 2008. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 130: 247-253.
29. Slattery ML, Curtin K, Anderson K, Ma KN, Edwards S, Leppert M, Potter J, Schaffer D, Samowitz WS. 2000. Associations between dietary intake and Ki-ras mutations in colon tumors: A population-based study. Cancer Res 60: 6935-6941.
30. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. 2009. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 101: 465-472.
31. Span M, Moerkerk PT, De Goeij AF, Arends JW. 1996. A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer (Pred Oncol) 69: 241-245.
32. Toyooka S, Tsukuda K, Ouchida M, Tanino M, Inaki Y, Kobayashi K, Yano M, Soh J, Kobatake T, Shimizu N, Shimizu K. 2003. Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR. Oncol Rep 10: 1455-1459.
33. Tsukuda K, Tanino M, Soga H, Shimizu N, Shimizu K. 2000. A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma. Biochem Biophys Res Commun 278: 653-658.
34. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R. 1989. Allelotype of colorectal carcinomas. Science 244: 207-211.
35. Wang JY, Hsieh JS, Chen FM, Yeh CS, Alexandersen K, Huang TJ, Chen D, Lin SR. 2003. High frequency of activated K-ras codon 15 mutant in colorectal carcinomas from Taiwanese patients. Int J Cancer 107: 387-393.
36. Wang JY, Hsieh JS, Lu CY, Yu FJ, Wu JY, Chen FM, Huang CJ, Lin SR. 2007. The differentially mutational spectra of the APC, K-ras, and p53 genes in sporadic colorectal cancers from Taiwanese patients. Hepatogastroenterology 54: 2259-2265.
37. Wong R, Cunningham D. 2008. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J Clin Oncol 26: 5668-5670.